Rakuten Medical
Rakuten Medical is a biotechnology company focusing on the development of its Alluminox™ treatment platform, designed to target and kill cancer cells using a photosensitizer and infrared light.
Funding and Financial Growth
Rakuten Medical completed a $119 million Series E financing round in March 2024. This funding round is aimed at furthering the development of its Alluminox™ platform, which is utilized for targeted cancer treatments. The significant capital raised reflects continued investor confidence in Rakuten Medical's innovative approaches and long-term growth potential.
Exclusive Licensing Agreement with Hikma Pharmaceuticals
Rakuten Medical signed an exclusive licensing agreement with Hikma Pharmaceuticals for the MENA region. This agreement focuses on the distribution and utilization of Rakuten Medical's Alluminox™ photodynamic cancer treatment. The partnership aims to extend access to life-saving cancer therapies across the Middle East and North Africa, enhancing global collaboration in oncological care.
Anniversary and Milestones
Rakuten Medical celebrated its 10-year anniversary on April 22, 2020. Over the past decade, the company has established itself as a leader in the biotechnology sector with a strong focus on innovative cancer treatments. This milestone highlights the company's longstanding commitment to advancing healthcare solutions through relentless research and development.
Alluminox™ Treatment Platform
Rakuten Medical is developing the Alluminox™ treatment platform, designed to selectively deliver a photosensitizer to targeted cells and use infrared light irradiation to kill cancer cells selectively. This novel technology represents a significant advancement in photodynamic therapy, offering a highly targeted approach to treating cancer with minimal impact on surrounding healthy tissues.
Clinical Trials and Research in Japan
Rakuten Medical is conducting a Phase I clinical trial in Japan for its RM-1995 photoimmunotherapy. This trial targets advanced or recurrent solid tumors with liver metastases and aims to evaluate the safety and efficacy of the treatment. Such clinical trials are crucial for validating the therapeutic potential of new treatments and bringing them closer to widespread clinical use.
Global Presence and Operations
Rakuten Medical has established offices in the United States, Japan, Taiwan, Switzerland, and India. This global presence underscores the company's commitment to leveraging international expertise and ensuring the widespread availability of its treatments. The strategic locations of these offices facilitate collaboration across different healthcare ecosystems and regulatory environments.